Therapeutics News and Research

RSS

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain.

17 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Protein complex may be an effective alternative to opioid pain medications

A drug targeting a protein complex containing two different types of opioid receptors may be an effective alternative to morphine and other opioid pain medications, without any of the side effects or risk of dependence, according to research led by the Icahn School of Medicine at Mount Sinai.

16 Jul 2013

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and BZL Biologics LLC, of New York, today announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.

15 Jul 2013

Ipsen, Harvard initiate collaboration to discover, develop botulinum toxins for neurologic diseases

Ipsen announced today that it has initiated a research and development collaboration on novel engineered botulinum toxins with Harvard Medical School.

15 Jul 2013

Clinical trial begins on ultrasound in combination with tPA to treat acute ischemic stroke

An international, Phase III clinical trial studying ultrasound in combination with a clot-busting medication to treat acute ischemic stroke has begun at The University of Texas Health Science Center at Houston (UTHealth).

12 Jul 2013

Novel therapeutic approach prevents dengue virus replication by artificial microRNAs

Mosquito-borne dengue viruses cause an estimated 50 million cases of human dengue fever a year and are a significant public health threat worldwide. A novel therapeutic approach prevents dengue virus from reproducing in humans by targeting and silencing key regions of the dengue genome essential for viral replication.

12 Jul 2013

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

12 Jul 2013

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.

11 Jul 2013

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Ohr Pharmaceutical, Inc., a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

10 Jul 2013

Researchers discover new class of antimalarial compounds

Despite renewed global efforts for eradication, malaria continues to exert devastating effects on human health. An estimated 220 million people are infected each year by malaria-causing Plasmodium parasites, which are transmitted by the bite of an infected mosquito. This enormous infection burden leads to some 660,000 lives lost to malaria each year, the majority of these young children in sub-Saharan Africa. While a vaccine to prevent malaria remains elusive, we depend on antimalarial compounds both to treat infections and prevent disease.

10 Jul 2013

Sorrento Therapeutics, BGN partner to develop therapeutic antibodies for Hepatitis C Virus

Sorrento Therapeutics, Inc. and B.G. Negev Technologies and Applications Ltd., the technology transfer company of Ben-Gurion University of the Negev, have announced an option and license agreement to develop therapeutic products to treat Hepatitis C Virus.

10 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Researcher uncover biomarkers from stem cells derived from bone marrow of ALS patients

Amyotrophic Lateral Sclerosis (ALS) is a devastating motor neuron disease that rapidly atrophies the muscles, leading to complete paralysis. Despite its high profile - established when it afflicted the New York Yankees' Lou Gehrig - ALS remains a disease that scientists are unable to predict, prevent, or cure.

10 Jul 2013

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.

9 Jul 2013

FORMA Therapeutics, CRT partner to discover therapeutic drug candidates against DUBs

FORMA Therapeutics and Cancer Research Technology, Ltd., the commercialization company of Cancer Research UK, announced today a bold research initiative to discover innovative tools, technologies and therapeutic drug candidates against a variety of protein homeostasis regulators called, deubiquitinating enzymes.

9 Jul 2013

Glythera secures £700k to advance development of new generation of biological therapeutics

Glythera Ltd is delighted to announce that it has successfully achieved a number of technical and commercial milestones which has resulted in the release of a second tranche of funding totalling £700k from IP Group and its managed fund, the Finance for Business North East Technology Fund.

9 Jul 2013

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis.

8 Jul 2013

Capricor to become wholly-owned subsidiary of Nile Therapeutics

Capricor, Inc., a privately held biotechnology company developing cardiac stem cell therapeutics to repair damaged heart muscle, and Nile Therapeutics, Inc. announced today that they have entered into a Merger Agreement under which Capricor will become a wholly-owned subsidiary of Nile Therapeutics, Inc. in an all-stock transaction.

8 Jul 2013

Study: ChemoFx chemoresponse assay can help identify platinum resistance in primary ovarian cancer

Precision Therapeutics, a leading life-science company dedicated to the improvement of patient outcomes in personalized medicine, today announced findings that support the ChemoFx chemoresponse assay as a tool to aid in the identification of platinum resistance in primary ovarian cancer, according to a presentation at the Annual Meeting of The Western Association of Gynecologic Oncologists June 26-29, in Seattle, Washington.

8 Jul 2013

Therapeutics News and Research

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Protein complex may be an effective alternative to opioid pain medications

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

Ipsen, Harvard initiate collaboration to discover, develop botulinum toxins for neurologic diseases

Clinical trial begins on ultrasound in combination with tPA to treat acute ischemic stroke

Novel therapeutic approach prevents dengue virus replication by artificial microRNAs

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Researchers discover new class of antimalarial compounds

Sorrento Therapeutics, BGN partner to develop therapeutic antibodies for Hepatitis C Virus

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Researcher uncover biomarkers from stem cells derived from bone marrow of ALS patients

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

FORMA Therapeutics, CRT partner to discover therapeutic drug candidates against DUBs

Glythera secures £700k to advance development of new generation of biological therapeutics

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

Capricor to become wholly-owned subsidiary of Nile Therapeutics

Study: ChemoFx chemoresponse assay can help identify platinum resistance in primary ovarian cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News